Scinopharm Taiwan Ltd, based in Taiwan, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for A leading process R&D and API Manufacturing service provider to the Global Pharmaceutical Industry.
One of their notable products is FULVESTRANT USP, with a corresponding US DMF Number 22611.
Remarkably, this DMF maintains an Active status since its submission on March 13, 2009, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of January 14, 2014, and payment made on September 03, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II